Barclays reiterated coverage on Reata Pharmaceuticals with a new price target
$RETA
Biotechnology: Pharmaceutical Preparations
Health Care
Barclays reiterated coverage of Reata Pharmaceuticals with a rating of Overweight and set a new price target of $43.00 from $180.00 previously